Cerebral infarction. Cerebral infarction
Conditions
Interventions
Intervention 1: Intervention: Cerebrolysin (30 mg for first 5 days during the first week and 10 mg for first 5 days in the second, third and fourth weeks) adding to routine therapy. Intervention 2: Co
Treatment - Drugs
Intervention: Cerebrolysin (30 mg for first 5 days during the first week and 10 mg for first 5 days in the second, third and fourth weeks) adding to routine therapy
Control: placebo in the same dose of the intervention group
Sponsors
Research Deputy, Shahid Beheshti University of Medical Sciences
Cobel Darou
Eligibility
Sex/Gender
All
Age
45 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients aged 45 to 85 years, the occurrence of acute cerebral ischemic attack (embolic or thrombotic), hospitalization during 12 hours of first symptoms of stroke, systolic blood pressure less than 200 and diastolic less than 100 mmHg Exclusion Criteria: recovery of neurologic symptoms after 4 hours of attack, hemorrhagic stroke or the occurrence of stroke in vertebrobasilar system with blood pressure =200/100 mmHg, seizures, Papilledema or rising intracranial pressure (RICP), neck stiffness or symptoms of brain stimulation, the condition of consciousness stupor and coma (GCS = 6), acute myocardial infarction, National Institutes of Health Stroke Scale (NIHSS) less than 7 and more than 24, hepatic or renal failure - heart failure, dementia initial appearance, acute infectious disease, doubt the Involvement in subsequent brain area (posterior circulation), pregnant women, symptoms of progressive neurologic defects, patients who are in other trials, patients received piracetam or calcium channel blockers (CCB), Patients who received r-TPA treatment during first 4 hours of symptoms
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical evaluation of motor ability (speech and motor ability of patients). Timepoint: daily. Method of measurement: MRS (Modified Rankin Scale), NIHSS (National Institutes of Health Stroke Scale). | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in the understanding of patients during the treatment. Timepoint: On days 3, 7, 15 and 30. Method of measurement: Asessment of CGIS (Clinical Global Impression Scale), PGS (Patient Global Satisfaction Score) and MMSE (Mini-Mental State Exam) by neurologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr kurosh Gharagozli
Shahid Beheshti University of Medical Sciences
Outcome results
None listed